Ductal carcinoma in situ (DCIS) is a pre-invasive lesion that is thought to be a precursor to invasive breast cancer (IBC).
DCIS makes up approximately 20 percent of newly diagnosed breast cancer cases and, unlike IBC, is not life-threatening. However, if left untreated, up to half of DCIS patients will develop IBC within 10 years, so clinical management has trended towards presuming all patients are progressors and treating them with surgery, radiation therapy, and pharmacological interventions. Thus, understanding the central biological features in DCIS that drive the transition to IBC is a critical unmet need for guiding appropriate patient care.
This whitepaper from Ionpath presents a case study in which researchers used multiplexed ion beam imaging (MIBI) to analyze spatial proteomic signatures of surgical resections covering the spectrum of breast cancer progression to understand how the tumor microenvironment changes with transition from DCIS to IBC.
Offered Free by: Ionpath, Inc.
See All Resources from: Ionpath, Inc.